Single triple-combination blood pressure pill after intracerebral hemorrhage
Official title: TRIple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure ConTrol With the TRICH Score
Run by The University of Hong Kong · NCT07458880 · Data updated 2026-11-12
This trial tests whether a single pill combining amlodipine, valsartan, and hydrochlorothiazide helps adults who recently had an intracerebral hemorrhage control their blood pressure.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 4 sites (Hong Kong, Hong Kong and 3 other locations) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | September 30, 2029 |
| Study ends | June 30, 2030 |
| Registry record updated | March 9, 2026 |
| Trial ID | NCT07458880 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) who had a spontaneous intracerebral hemorrhage within the past week, with premorbid mRS ≤3, TRICH score ≥3, and ability to perform home blood-pressure monitoring and follow-up activities are ideal candidates.
✕Probably not a fit
Patients with admission SBP <160 mmHg, Glasgow Coma Score <9, severe renal impairment (eGFR <30), known hypersensitivity or contraindication to amlodipine, valsartan, or hydrochlorothiazide, or inability to monitor BP at home are unlikely to qualify or benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional trial compares a fixed-dose triple-combination antihypertensive pill (Exforge HCT®) to the same three drugs given individually in adults soon after spontaneous intracerebral hemorrhage. Eligible patients are adults with recent ICH (within one week), premorbid function mRS ≤3 and TRICH score ≥3, who can perform home blood-pressure monitoring and follow-up. Patients with very low admission SBP, severe renal impairment, severe decreased consciousness, or contraindications to any component are excluded. The main approach is practical: improve adherence and BP control using a single-pill regimen to reduce recurrent ICH and cardiovascular events.
Why it matters
Potential benefit: If successful, this approach could improve blood pressure control and adherence with a simpler single-pill regimen, potentially lowering the risk of recurrent ICH and other cardiovascular events.
How similar studies have gone: Combination antihypertensive therapy and aggressive BP lowering after ICH have supportive evidence for reducing recurrence, but using a single fixed triple-combination pill specifically in recent ICH survivors is relatively novel and not yet widely proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Spontaneous ICH 2. Age ≥18 years 3. Premorbid modified Rankin Scale of ≤3 4. TRICH score ≥3 5. Within 1 week of ICH Exclusion Criteria: 1. Glasgow coma score \<9 2. Expected life expectancy of six months 3. Admission SBP \<160mmHg 4. Severe renal impairment, estimated glomerular filtration rate using CKD-EPI formula \<30 ml/min/1.73m2 5. Inability to perform home BP monitoring 6. Inability to participate in follow-up activity 7. Hypersensitivity to study drug 8. Known contraindication to amlodipine 9. Known contraindication to valsartan 10. Known contraindication to hydrochlorothiazide 11. Any conditions that investigator deems that patient is not suitable of any component of the triple pill or antihypertensive medications in general
Where it's running
-
Queen Mary Hospital
Hong Kong, Hong Kong, Hong Kong Recruiting -
Princess Margaret Hospital
Hong Kong, Hong Kong, Hong Kong Not yet recruiting -
Ruttonjee Hospital
Hong Kong, Hong Kong, Hong Kong Not yet recruiting -
Yan Chai Hospital
Hong Kong, Hong Kong, Hong Kong Not yet recruiting
Study contacts
- Study coordinator: Kay Cheong TEO
- Email: kcteo@hku.hk
- Phone: +852 2255 5318
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Smartphone-based EEG to detect hidden awareness in ICU patients with brain injuries
Researchers will test a smartphone-enabled EEG to see if it can reveal Cognitive Motor Dissociation in ICU patients who can’t show commands at bedside.
-
Chinese multicenter group studies spontaneous intracerebral hemorrhage in adults
This study tests how a large group of adults with spontaneous intracerebral hemorrhage (and a healthy control group) progress over time to understand outcomes and determinants of recovery.
-
Rapid Evacuation and Access of Cerebral Hemorrhage Registry: observing minimally invasive surgery outcomes
This registry collection tests how minimally invasive brain-bleed procedures work in real patients with acute spontaneous intracerebral hemorrhage.
-
Vitamin D treatment after intracerebral hemorrhage
This will try giving higher-dose vitamin D to adults within 96 hours of an intracerebral hemorrhage to see if it helps clear the bleed faster and is safe.
-
Prototype CT tools for minimally invasive intracerebral hemorrhage evacuation
This project will test two Siemens prototype CT tools—a perfusion feature and an automatic hemorrhage detector—to see if they help doctors planning and performing minimally invasive brain-bleed (intracerebral hemorrhage) evacuation in adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.